BioNano Genomics Inc vs Modine Manufacturing Company — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Modine Manufacturing Company trades at $226.71 (market cap $12.19B). The key difference: Modine Manufacturing Company is far larger — about 923.5× BioNano Genomics Inc's market cap, and Modine Manufacturing Company is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | MOD | |
|---|---|---|
Market Cap | $13.20M | $12.19B |
Sector | Health | Technology |
52-Week High | $4.92 | $306.89 |
52-Week Low | $1.09 | $90.02 |
Enterprise Value | $15.81M | $12.55B |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Modine (MOD) is trading at $234.28, down 4.73% amid bearish technical signals, though it maintains strong analyst support with a $328.80 consensus price target. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.71 exceeding estimates by 10%. Fundamentals show revenue growth to $2.58 billion in 2025 but declining net margins, while the stock trades at elevated valuation multiples including a P/E of 101.58.
The outlook remains positive based on analyst consensus and recent executive appointments, but risks include high valuation, margin pressure, and technical weakness. Investment opportunity lies in the 40% upside to price targets if execution continues, though investors face volatility from supply chain challenges and competitive pressures in the thermal management sector.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →